Is Dendreon's Downgrade Deserved?

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world.

In today's edition, David discusses whether Dendreon's recent downgrades are deserved. Shares have lost more than a third of their value over the past month, as investors concerned with Provenge's slow launch feel the looming shadow of Johnson & Johnson's Zytiga. Can Dendreon recapture the magic, or are analysts correct that Provenge's high price and looming competition will relegate it to an afterthought treatment? Watch and find out.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time this article was published David Williamsonowns shares of Johnson & Johnson and Dendreon. The Motley Fool owns shares of Dendreon and Johnson & Johnson.Motley Fool newsletter services recommendJohnson & Johnson and Vertex Pharmaceuticals. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story